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Abstract
Background: USP18 (ubiquitin-specific protease 18) removes ubiquitin-like modifier interferon stimulated gene 15
(ISG15) from conjugated proteins. USP18 null mice in a FVB/N background develop tumors as early as 2 months of
age. These tumors are leiomyosarcomas and thus represent a new murine model for this disease.
Methods: Heterozygous USP18 +/− FVB/N mice were bred to generate wild-type, heterozygous and homozygous
cohorts. Tumors were characterized immunohistochemically and two cell lines were derived from independent
tumors. Cell lines were karyotyped and their responses to restoration of USP18 activity assessed. Drug testing and
tumorigenic assays were also performed. USP18 immunohistochemical staining in a large series of human
leiomyosacomas was examined.
Results: USP18 −/− FVB/N mice spontaneously develop tumors predominantly on the back of the neck with most
tumors evident between 6–12 months (80 % penetrance). Immunohistochemical characterization of the tumors
confirmed they were leiomyosarcomas, which originate from smooth muscle. Restoration of USP18 activity in
sarcoma-derived cell lines did not reduce anchorage dependent or independent growth or xenograft tumor formation
demonstrating that these cells no longer require USP18 suppression for tumorigenesis. Karyotyping revealed that both
tumor-derived cell lines were aneuploid with extra copies of chromosomes 3 and 15. Chromosome 15 contains the
Myc locus and MYC is also amplified in human leiomyosarcomas. MYC protein levels were elevated in both murine
leiomyosarcoma cell lines. Stabilized P53 protein was detected in a subset of these murine tumors, another feature of
human leiomyosarcomas. Immunohistochemical analyses of USP18 in human leiomyosarcomas revealed a range of
staining intensities with the highest USP18 expression in normal vascular smooth muscle. USP18 tissue array analysis
of primary leiomyosarcomas from 89 patients with a clinical database revealed cases with reduced USP18 levels had
a significantly decreased time to metastasis (P = 0.0441).
Conclusions: USP18 null mice develop leiomyosarcoma recapitulating key features of clinical leiomyosarcomas and
patients with reduced-USP18 tumor levels have an unfavorable outcome. USP18 null mice and the derived cell lines
represent clinically-relevant models of leiomyosarcoma and can provide insights into both leiomyosarcoma biology
and therapy.
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Background
Soft tissue sarcomas are heterogeneous malignancies of
mesenchymal origin. They arise from supporting tissues
of the body including adipose, muscle and fibrous con-
nective tissue [1]. Although relatively rare, with an inter-
national incidence ranging from 1.8 to 5 cases per 100,000
per year, approximately 50 % of patients succumb to this
malignancy [2–4]. Median survival for patients with ad-
vanced or metastatic sarcoma is only 12 months [5–7].
There are currently limited therapeutic options for those
diagnosed with recurrent or advanced stage sarcoma.
Surgery and radiation are the mainstays of treatment with
doxorubicin being the most frequently used single chemo-
therapeutic agent, providing only 10–30 % objective re-
sponses, but no increase in survival [8, 9]. Hence, there is
a need to identify new therapeutic approaches for these
diverse tumors.
Leiomyosarcomas arise from smooth muscle and belong
to the subgroup of sarcomas that have a complex, unbal-
anced karyotype, usually harboring non-specific genetic
alterations and chromosomal instability [10, 11]. Consistent
with other sarcomas with complex karyotypes, leiomyosar-
comas frequently deregulate P53 expression [12–14].
Effective targeted therapy for the complex karyotype-
associated sarcomas is likely hindered by their tumor het-
erogeneity. If there were a way to identify subsets of sarco-
mas with specific genetic alterations, this would improve
the classification or treatment outcomes for these malig-
nancies. For instance, polysomy of chromosome 8 in
humans (syntenic to polysomy 15 in mice) is reported in
complex sarcomas including leiomyosarcomas [15, 16].
Notably, MYC is found on chromosome 8 and is a fre-
quently overexpressed oncogene in human cancers. Indeed,
MYC overexpression in a subset of leiomyosarcomas was
associated with decreased metastasis-free survival [17].
There are few tractable mouse models that mimic the
histopathology and molecular characteristics of human
leiomyosarcomas. New mouse models could be instrumen-
tal in therapeutic development.
Ubiquitin-specific protease 18 (USP18) is a deubiquiti-
nase for an interferon-regulated ubiquitin-like process,
ISGylation [18]. This is the conjugation of interferon
(IFN)-stimulated gene 15 (ISG15), a 15kDa ubiquitin-like
moiety, to diverse target proteins [19, 20]. USP18 knock-
out mice were initially generated on a C57Bl/6 and 129
mixed background [21]. These mice displayed neuro-
logical symptoms and hydrocephalus and did not survive
beyond 5 months [21]. Subsequent generation of USP18
knockout mice on a pure C57Bl/6 background found
homozygous deletion of USP18 was embryonic lethal [22].
In contrast, this phenotype was not seen in the USP18
knockout FVB background mice. C57Bl/6-129-USP18
knockout mice were also hypersensitive to type I IFN as
seen when they were treated with the IFN-inducer, poly-
IC; this was fatal for USP18 knockout, but not for the
wild-type mice [23]. Recently, human ISG15 deficiency
was found to cause a decrease in USP18 accumulation
and this was hypothesized to cause the loss of negative
feedback of type I interferon signaling in these patients
leading to auto-inflammation [24].
USP18 overexpression is associated with augmented
oncogene or growth factor receptor expression such as
the epidermal growth factor receptor (EGFR) and tumor-
promoting effects in acute promyelocytic leukemia, kidney
and lung cancer [25–28]. Intriguingly, we report here the
previously unrecognized development of spontaneous
subcutaneous sarcomas, histopathologically diagnosed as
leiomyosarcoma, in FVB-USP18 knockout mice. These
murine sarcomas recapitulate critical characteristics of
human leiomyosarcoma including aneuploidy, overexpres-
sion of MYC and deregulation of P53.
USP18 analysis of clinical leiomyosarcoma revealed
abundant staining in normal smooth muscle cells, which
was retained by some sarcomas, but lost in others. While
loss of USP18 did not significantly impact overall sur-
vival or disease-free survival, it did significantly decrease
the time to metastasis indicating a key role for USP18
levels in leiomyosarcoma clinical biology.
Cell lines were independently derived from sarcomas
that arose in different mice. These sarcomas were histo-
pathologically diagnosed as leiomyosarcomas. Cell lines
were aneuploid and overexpressed MYC relative to
mouse embryonic fibroblasts (MEFs). These lines formed
rapidly growing subcutaneous sarcomas following trans-
plantation into athymic and immunocompetent mice.
These murine sarcoma cell lines, when coupled with the
parental USP18 null mice, comprise tractable models to
accelerate the discovery and development of new therap-
ies for human leiomyosarcoma.
Methods
Mice
FVB-USP18 heterozygous mice were purchased from the
Jackson Laboratory. These mice were bred to generate
FVB-USP18 knockout mice. Generation of FVB-USP18
knockout mice is previously described [21, 29]. Genotyp-
ing for the knockout was done using polymerase chain
reaction (PCR) assays according to a previously pub-
lished protocol from the Jackson Laboratory (#007225).
Mice were bred in a non-pathogen environment, accord-
ing to an Institutional Animal Care and Use Committee
(IACUC)-approved protocol at Dartmouth. All mice ex-
periments were done in accordance with this protocol.
Animals are housed in cages with a 68 inch squared area
with no more than 4 adult mice per cage. They live with
a 12 h light/12 h dark light schedule at a humidity of
30–70 % and a temperature of 72 +/− 2 0 F. Mice receive
ad libitum food (Teklad Irradiated Rodent Diet 2918)
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and water. Bedding is hardwood chip and at a depth of
0.25 inches.
Once tumors were detected in USP18 null mice, animals
were closely monitored three times per week and weighed.
Mice with greater than 10% body weight loss or with a
tumor that was causing substantial clinical symptoms
were euthanized using IACUC-approved procedures.
Tumor tissues
Acquisition of tissue specimens and clinical information
and subsequent analyses were approved by the Institu-
tional Review Board (IRB) of The University of Texas
MD Anderson Cancer Center (UTMDACC) and Dart-
mouth Hitchcock Medical Canter (DHMC). Patients
provided written informed consent.
Generation of USP18 knockout cell lines and cell culture
Two independent cell lines (designated KHC-1and KHC-2)
were generated from subcutaneous tumors, using described
methods [30]. Cells were cultured on tissue culture plates
in RPMI-1640 media with 10 % fetal bovine serum (FBS).
These cells have been continuously cultured for up to 40
passages at 5 % CO2 and at 37° C in a humidified incubator.
Cell karyotyping analysis confirmed these cells were of
murine origin and immunohistochemical analysis estab-
lished they retained expression of antigens consistent with
the original tumors. SK-LMS-1 human leiomyosarcoma
cells were purchased from ATCC where cell identity is con-
firmed using standard short tandem repeat (STR) analyses.
SK-LMS-1 cells were cultured in Eagle’s Minimum Essen-
tial medium (EMEM).
The siRNAs for knockdown experiments were from
Ambion. MYC siRNA #1 (#s70224), MYC siRNA #2
(#s70226) and negative control (#4390843) were indi-
vidually transfected into cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions
and with triplicate replicate transfections. Protein was
collected and analyzed by immunoblot assays to verify
knockdown 24 h post-transfection. To quantify MYC
protein knockdown, densitometry readings of immuno-
blots (from 3 independent transfections) were measured
using NIH ImageJ analyses. Cell growth was assessed 72
h post-transfection using the CellTiter-Glo assay (Pro-
mega). Growth comparisons were normalized to cells
transfected with control siRNA.
Reconstitution of USP18 in sarcoma cell lines
Lipofectamine 2000 (Invitrogen) was used to transfect
the pRetroX-IRES-ZsGreen1-USP18 retroviral vector or
an empty retrovirus (Clontech) into Plat-A retroviral
packaging cells according to manufacturer’s protocol
(Cell Biolabs). Viral supernatants were collected after 48
h. KHC-1 and KHC-2 cells were transduced with the
respective viral supernatants in regular culture media
supplemented with polybrene (4g/mL) (Sigma). Green
fluorescent protein expressing cells were sorted after 48
h using a FACStar Plus cytometer (Becton Dickinson).
Drug treatments, proliferation and apoptosis assays
KHC-1, KHC-2 and human leiomyosarcoma SK-LMS-1
cells were each treated with doxorubicin (0.2μM) or with
interferon-beta (IFNβ) (500 units/mL) (Sigma). Cell growth
was assayed using a CellTiter-Glo Luminescent assay (Pro-
mega) in four independent, replicate experiments (each
performed in at least triplicates). Unless stated otherwise,
growth was measured after 72 h. Apoptosis was analyzed
using Annexin V:FITC and PI positivity in flow cytometry
assays according to the manufacturer’s instructions (AbD
Serotec). All experiments were performed at least 3 times.
Immunoblot analyses
Cells were lysed in modified radioimmunoprecipation buf-
fer (RIPA) [31] supplemented with protease and phosphat-
ase inhibitors (Sigma). Proteins were resolved on SDS-
PAGE gels and transferred to nitrocellulose membranes
(primary antibodies listed in Additional file 1: Table S1).
Membranes were blocked in tris-buffered saline with 0.1 %
Tween 20 (TBS/Tween) plus 5 % non-fat milk powder.
Primary antibodies were diluted in this blocking buffer or
in 5 % bovine serum albumin (BSA) in TBS/Tween. Pri-
mary antibodies were detected with horseradish peroxidase
(HRP) conjugated secondary antibodies (Santa Cruz and
GE Healthcare) and visualized using Luminata Forte
chemiluminescent HRP detection reagents (Millipore).
Anchorage independent growth
Cells were plated in 6 well plates (104 cells/well) in 0.5 %
agarose, as before [31]. The agar and cell suspensions were
layered onto a 1 % base agarose in RPMI-1640 media con-
taining 10% FBS. After formation of the top agar, 1mL of
RPMI-1640 medium containing 10% FBS was overlaid be-
fore incubation at 37°C in a 5 % CO2humidified incubator
for 14 days. Colonies greater than five cells were counted
using a microscope in four independent experiments.
Orthotopic sarcoma model
Cells for subcutaneous flank implantation into nude
mice were resuspended in a 1:1 mixture of phosphate
buffered saline (PBS) and reduced growth factor Matri-
gel (BD Biosciences). The cell number used for athymic
nude mice (01B74/Athymic NCr-nu/nu, NCI) was 2.7 ×
105 for the KHC-1 line, 1 × 105 for KHC-2 cells and for
syngeneic NCr-FVB (NCI) mice this was 1 × 105 KHC-1
cells. Four 8 week old female mice were used per cell
line for subcutaneous tumor growth analysis and were
randomly assigned the different cell lines. Mice were
weighed and tumor size was measured biweekly with
calipers. The orthotopic mouse tumor experimental
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protocol was reviewed and approved by Dartmouth's In-
stitutional Animal Care and Use Committee (IACUC).
Mice were sacrificed using an IACUC-approved protocol
when tumor diameter measured 15 mm or if mice be-
came symptomatic and/or cachectic (loss of 10 % or
more of body weight). Tumor volume was calculated
using the formula 0.5 × length × (width)2 where width is
defined as the smallest diameter.
Histopatology
Routine hematoxylin and eosin (H & E) and immuno-
staining were performed as described in the Additional
file 2.
Statistics
Two-tailed t tests were used for statistical analysis unless
otherwise noted. Statistical significance was defined as
*P < 0.05 and **P < 0.01. For tissue microarray USP18
immunohistochemical scores were grouped based on
comparison to normal muscle as 1+ (low) or 2-3+
(retained). This scoring system is previously described
[32]. For primary soft tissue tumors only, the method of
Kaplan and Meier was used to assess outcomes in rela-
tion to USP18 expression. Univariable and multivariable
Cox proportional hazards regression models were used
to estimate associations between USP18 expression and
overall survival (OS), disease-specific survival (DSS) and
time to first metastasis, with alpha of 0.05 considered as
significant.
Results
FVB-Usp18 knockout mice develop leiomyosarcomas
USP18 knockout mice on an FVB background were gen-
erated and their genotypes confirmed by PCR assays
(Fig. 1a). About 80% of FVB-USP18 knockout mice de-
veloped clinically-detectable subcutaneous tumors in the
trunk or neck regions (Fig. 1b and c). This was in con-
trast to wild-type and heterozygous USP18 mice where
no such tumors were detected (Fig. 1c). In some USP18
knockout mice, dystrophic calcifications appeared with
or without tumor development (Additional file 1: Figure
S1). H & E staining of formalin-fixed sections of these
murine tumors revealed anaplastic tumors with numer-
ous mitotic bodies and a spindle-like morphology
(Fig. 1d). Some of the tumors had giant cells (Fig. 1d).
The dystrophic calcification could be a precursor lesion
for these tumors. Calcification is often seen in leiomyo-
mas, which are benign smooth muscle cell malignancies,
but has also been seen in leiomyosarcomas [33].
The sarcomas occurred in USP18 null mice as early as
2 months of age (Table 1). Younger mice (less than 6
months old) tended to exhibit more dystrophic calcifica-
tions unlike the gross tumor development in mice older
than 6 months (Additional file 1: Figure S1A). Most of
the USP18 knockout mice exhibited palpable sarcomas
at ages from 6 months to 12 months (Table 1 and
Fig. 1b). While there were more male than female mice
displayed in Table 1, this was not due to a sex-linked
difference in sarcoma development. The percentage of
mice that developed sarcomas was similar for males and
females.
To further characterize these sarcomas, histopathological
analyses were performed. These sarcomas were of mesen-
chymal origin because they were typically negative for the
epithelial marker cytokeratin (Table 1). S100, a marker for
melanomas and some neural-derived tumors was absent in
every sarcoma except for one with rare nuclear staining. Of
the mesenchymal-specific cell markers, all 13 of the tumors
stained diffusely positive for smooth muscle actin. For
desmin, 12 of 13 stained positively with 1 negative and 1
with rare staining. Calponin staining was the lowest of the
three mesenchymal markers examined and it exhibited
diffusely positive staining in 5 tumors and focal staining in
another 5; 2 tumors stained negatively and another tumor
was not evaluable (Table 1). All the tumors analyzed
were classified as high-grade leiomyosarcomas and
these sarcomas exhibited necrosis. A representative
sarcoma and sarcoma derived cell line are shown in
Fig. 1e and f. For the cell line shown in Fig. 1f and
for some of the other sarcomas there was some het-
erogeneity of staining with calponin and desmin.
Mice lacking the tumor suppressor P53 spontaneously
develop tumors, specifically lymphomas and sarcomas
[34]. Studies of clinical leiomyosarcomas have shown
frequent deregulation of P53 [12]. In this study, 5 of 13
sarcomas showed abundant staining for P53 indicating
stabilization and deregulation of this protein. Figure 1
shows a tumor with abundant nuclear P53 and another
that was negative for P53 staining (Fig. 1g).
Restoration of USP18 expression in USP18 null
leiomyosarcoma cell lines
Leiomyosarcoma cell lines were derived from two differ-
ent mice with sarcomas and were designated as KHC-1
and KHC-2, respectively (Fig. 2a). Loss of the USP18
gene in each cell line was confirmed by PCR assay geno-
typing. To determine if restoring USP18 activity reversed
tumorigenicity in these cell lines, each was retrovirally-
transduced with either human USP18 or an empty
vector. USP18 functional reconstitution was demon-
strated by decreased ISG15 conjugates in response to
IFNβ treatment versus parental and empty vector con-
trol cells (Fig. 2a).
There was no statistically significant difference in
monolayer or soft agar growth assays between KHC-1
and KHC-2 cells independently stably transfected with
an empty vector or the USP18 expression vector (Fig. 2b
and c). When these leiomyosarcoma cell lines were each
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transplanted into athymic mice (n = 4), palpable tu-
mors arose within 2 to 3 days of subcutaneous im-
plantation. Tumors grew at a similar rate and reached
their predetermined study endpoint diameter of
15mm within 10–20 days (data not shown). Engrafted
tumors were harvested from athymic mice and USP18
expression in the USP18 stably transfected tumor-forming
cells was detected (Additional file 1: Figure S1B). Tumor
histology was similar to the sarcomas in USP18 null mice.
There was no statistically significant difference observed
in tumor growth between cells transduced with an empty
vector versus those with restored USP18 activity (Fig. 2d).
e f
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Fig. 1 FVB-USP18 knockout mice develop sarcomas. a: PCR genotyping assays of USP18−/−, USP18+/−, and USP18+/+ genomic DNA (null allele,
370bp and wild-type allele 151bp). b: USP18 null mice with tumors. c: H & E staining of representative sarcomas. The solid arrow
indicates a multinucleate giant cell. The spindle cell characteristic of the sarcomas is depicted in the right panel and the hatched arrow indicates a
mitotic cell. d: Kaplan-Meier curve is displayed depicting the times when sarcoma development necessitated euthanasia in USP18−/− mice versus
USP18+/+ and USP18+/−mice, respectively. USP18 null mice significantly developed sarcomas (P < 0.0001) while no sarcomas were seen in wild-type
or heterozygous mice. e: H & E staining of a representative murine leiomyosarcoma in a USP18 −/− mouse is displayed along with the expression
profiles for S100, cytokeratin (AE1/AE3), desmin, calponin and SMA (smooth muscle actin). f: A representative leiomyosarcoma cell line (KHC-2) was also
examined for the same markers displayed in panel E. A phase-contrast image of this cell line is provided. g: The P53 immunostaining is of two USP18
−/− murine leiomyosarcomas, one positive for nuclear P53 and one negative
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This experiment was repeated in immunocompetent
FVB/N mice and there was no difference in tumor
growth (or immune infiltrates) detected between cells
transplanted with restored USP18 activity and controls
(n = 4). Tumor onset and immune infiltrates were similar
to that observed in athymic mice (data not shown).
Hence, an intact immune system did not affect murine
leiomyosarcomas growth. While loss of USP18 preceded
sarcoma formation, these sarcoma cell lines did not de-
pend on loss of USP18 expression for survival, growth
or tumorigenicity.
USP18 null leiomyosarcoma cell lines are aneuploid and
overexpress MYC
Since leiomyosarcomas can exhibit aneuploidy [10, 11],
cytogenetic analyses were performed on KHC-1 and
KHC-2 cell lines. Standard karyotyping by G-banding and
spectral karyotyping (SKY) were used to characterize the
cells and both were aneuploid (Fig. 3a and b). The KHC-1
cell line had trisomy 3, tetrasomy 15, deletions of chromo-
somes 3 and 4 and a derivative chromosome 9. KHC-2
cells showed trisomy 3, 12 and 15, trisomies with deriva-
tives on 8 and 16, and a translocation of chromosomes 6
and 11 (Fig. 3b). Chromosome 15 contains the loci for
Myc (orthologous to a chromosome 8 region in humans).
Chromosome 15 is also the site of two proto-oncogenes of
the Wnt family, Wnt1 and Wnt10b [35]. Aneuploidy is
frequent in clinical leiomyosarcomas and the chromo-
somal sites shown here are homologous to those altered
in human leiomyosarcomas [15, 16].
Given that both cell lines exhibited polysomy in
chromosome 15, which carries the Myc locus (Fig. 3a
and b), MYC protein levels were examined in KHC-1
and KHC-2 cells. Compared to wild-type mouse embry-
onic fibroblasts (MEFs) and NIH-3T3L1 cells, MYC pro-
tein levels were higher in the leiomyosarcoma cell lines
(Fig. 3c). To determine the effect of MYC repression in
these cell lines, two different MYC siRNAs were indi-
vidually transfected into each cell line and growth effects
were compared with controls after 72 h. Knockdown of
MYC protein in each cell line was confirmed (Fig. 3d)
with MYC protein levels decreased to between 12–27 %
and 25–35 % of controls in KHC-1 cells and KHC-2
cells, respectively, as determined by densitometry from 3
independent experiments. Reduced MYC expression
modestly, yet significantly inhibited growth of both cell
lines (Fig. 3e and f).
IFNβ and doxorubicin treatments of murine and human
leiomyosarcoma cell lines
USP18 knockout mice on a C57Bl/6 background were
hypersensitive to type I IFN [23]. Given this, we sought
to treat USP18 null sarcoma cell lines with IFNβ to
determine if they exhibited type I IFN hypersensitivity.
Growth inhibition occurred 24, 48 and 72 h after IFNβ
treatment, with the most prominent inhibition at 72 h
(Fig. 4a and b, left panels). Both of these leiomyosarcoma
lines exhibited apoptosis after IFNβ treatments (Fig. 4a
and b, right panels). Independent treatments of a hu-
man leiomyosarcoma cell line with identical IFNβ and
Table 1 Molecular pathology of the murine sarcomas
Mouse # (M/F) Age (months) S100 Cytokeratin SMA Desmin Calponin p53
1 (M) 9 0 0 3+ 2+ focal-1+ 3+
2 (M) 10 0 rare 2+ 3+ 2+ 3+ 0
3 (M) 8 0 rare 2+ 3+ 3+ 0 1+
4 (M) 10 Rare nuclei rare 1+ 3+ 2+ 2+ 1+
5 (M) 9 0 0 3+ 3 focal-1+ 0
6 (F) 7 0 0 2+ 0 NA* 0
7 (F) 9 0 0 3+ rare 2+ 3+ 3+
8 (M) 10 0 0 2+ 1+ focal-1+ 3+
9 (F) 10 0 0 2+ 3+ 0 0
10 (M) 9 0 rare 1+ 2+ 3+ 2+ 2+
11 (M) 8 0 0 3+ 3+ 2+ 1+
12 (M) 2 0 0 1+ 1+ focal-2+ 0
13 (M) 9 0 0 2+ 2+ focal-1+ 3+
KHC-1 N/A 0 0 3+ 2+ focal-2+ ×
KHC-1 N/A 0 0 3+ 2+ 2+ ×
This Table provides scoring for the different marker antibodies used to diagnose the histopathology of these sarcomas. The markers include S100, cytokeratin
(AE1/AE3), smooth muscle actin (SMA), desmin, calponin and p53. All staining was diffuse unless otherwise noted. N/A refers to not applicable. The abbreviations
M and F refer to male and female, respectively
NA* is Not Evaluable and x is Not Done
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doxorubicin concentrations conferred modest growth
inhibition (Additional file 1: Figure.S3). Due to the
slower growth characteristics of this cell line, it cannot be
assumed that the USP18 null cells are hypersinsitive to
IFNβ. Treatment of the murine USP18 null cell lines with
restored USP18 activity did not alter IFNβ response. This in-
dicated that USP18 levels did not affect IFNβ sensitivity in
these cells when grown in vitro (Additional file 1: Figure.S4).
Immunoblot analyses of the murine cell lines uncov-
ered constitutive phosphorylation of STAT3, which is
oncogenic in other systems [36]. With development of
inhibitors of the upstream kinase Janus kinase 2 (JAK2),
it is possible to target this pathway. KHC1 and KHC2
cells were each growth inhibited by the JAK2-STAT3
pathway inhibitor JSI-124 (Additional file 1: Figure. S2)
at doses that inhibited JAK2-STAT3 signal transduction
(Additional file 1: Figure. S2C). These sarcoma cell lines
were also sensitive to clinically achievable doxorubicin
dosages that caused decreased proliferation and in-
creased apoptosis in these cells (Fig. 4c and d). Thus,
these new murine leiomyosarcoma cell lines established
antineoplastic activity of known and new agents for
treatment of leiomyosarcomas.
USP18 expression in human leiomyosarcomas
To establish the translational research relevance of these
pre-clinical findings, USP18 immunohistochemical studies
were performed in 21 different human leiomyosarcomas
Fig. 2 Reconstitution of USP18 in USP18−/− sarcoma cell lines did not reverse tumorigenesis. a: Stable transfection of human USP18 restored
USP18 deconjugase activity in the USP18 knockout KHC-1 and KHC-2 leiomyosarcoma cell lines. The ISG15 conjugates were more prominent after
24 h treatment with IFNβ. b: Monolayer growth assays of empty vector versus USP18 reconstituted cells over 72 h expressed as fold difference
versus control cells. c: Anchorage-independent growth for KHC-1 and KHC-2 cell lines, with or without USP18 reconstitution. d: Tumorigenesis of
KHC-1 and KHC-2 cells in athymic mice in USP18 reconstituted cells versus vector control cells. Error bars represent standard deviation
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(Additional file 1: Table S2). Specimen site is indicated since
samples were from a mix of primary tumors, metastases
and tumors that had recurred. A representative immuno-
histochemical analysis of USP18 levels in histopathologic-
ally normal human lung and in clinical leiomyosarcomas is
displayed in Fig. 5a and b. Findings revealed prominent
USP18 immunostaining in lung macrophages (Fig. 5a) and
also in histopathologically normal vascular smooth muscle
cells with reduced expression relative to the adjacent leio-
myosarcoma (Fig. 5b). Some leiomyosarcomas expressed
USP18 levels approaching that of histologically nor-
mal smooth muscle (Fig. 5b center panel). Vascular
smooth muscle is the cell of origin for some leiomyo-
sarcomas [37, 38].
To extend this analysis, USP18 levels were examined in
a human leiomyosarcoma tissue microarray. Compared to
normal tissues where USP18 staining was high, (vascular
smooth muscle cells served as a control), there was a sub-
group of leiomyosarcomas with reduced USP18 immuno-
staining (Fig. 5c). Clinical data were available for 89
Fig. 3 Leiomyosarcoma cell lines are aneuploid and overexpress MYC. a and b: Cytogenetic analyses showed that both KHC-1 and KHC-2 had
polysomy of chromosomes 3 and 15 (black arrows). c: Immunoblot analysis of MYC protein as shown for KHC-1 and KHC-2 cell lines as compared
to NIH-3T3L1 and mouse embryonic fibroblast (MEF) cells. d: Immunoblot analysis of MYC levels validated knockdown by two independent
siRNAs in KHC-1 and KHC-2 cells. e and f: Analysis of cell growth in KHC-1 and KHC-2 cells transfected with MYC or control siRNAs






























































































































































































Fig. 4 USP18−/− leiomyosarcoma cell lines are sensitive to IFNβ and clinically-achievable concentrations of doxorubicin. a and b: Cell growth and
apoptosis analysis of KHC-1 and KHC-2 cells treated with IFNβ (500 units/mL). c and d: Cell growth and apoptosis analysis of KHC-1 and KHC-2






Fig. 5 Immunohistochemical analyses in human leiomyosarcoma cases and normal vascular smooth muscle and outcomes analysis. a: USP18
staining of normal lung tissue. Blue arrow indicates a USP18 positive macrophage. b: USP18 staining of clinical leiomyosarcoma with adjacent
normal smooth muscle tissue. Abundant USP18 expression in vascular smooth muscle cells is highlighted with black arrows. Red arrows indicate
leiomyosarcoma. c: Relative levels of USP18 in normal smooth muscle and in a series of leiomyosarcoma. d: Time to development of first
metastasis for 89 primary uterine and soft tissue leiomyosarcoma patients
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primary uterine and soft tissue leiomyosarcomas. In
univariable Cox proportional hazards analysis, retained
USP18 expression was associated with prolonged time to
first metastasis (HR 0.4543, 95 % CI 0.2107–0.9795,
p = 0.0441) (Fig. 5d). USP18 levels were not predictive
of overall survival (OS) (p = 0.72) or disease free sur-
vival (DSS) (p = 0.3371) (data not shown). Multivariate
analysis was performed including factors shown in
prior analyses as clinically prognostic in leiomyosar-
coma [32]. In the current analysis, USP18 retained expres-
sion predicted longer time to metastasis (p = 0.0213).
Discussion
Leiomyosarcomas have complex karyotypes and treat-
ment options are limited [39, 40]. Clinically-relevant
murine leiomyosarcoma models should help develop in-
novative therapies for these sarcomas. Few soft-tissue
murine models of leiomyosarcoma exist. Inactivation of
PTEN in smooth muscle cells produced small mice with
smooth muscle hyperplasia affecting blood vessels and
the urinary and intestinal tracts, but not in the uterus
[41]. Expression of the T antigens of the SV40 early re-
gion resulted in a narrow tissue-specific distribution of
tumors. All female animals developed large uterine leio-
myosarcomas by 3 months and most males exhibited
enlarged seminal vesicles from smooth muscle hyperpla-
sia [42]. In an experiment to specifically inactivate
BRCA1, P53 and Rb in murine ovarian epithelial cells,
tumors arose instead from adjacent smooth muscle and
were diagnosed as leiomyosarcomas [43]. Thus, distinct
genetic changes can cause leiomyosarcomas to arise
from different primary sites.
The 3-MCA-carcinogen murine fibrosarcoma model
provided insights into tumor immunology and cancer
immunoediting. Mice with specific immune defects are
particularly susceptible to chemical-induced carcinogen-
esis. Perforin-1, IFN-γ, STAT-1 and T cells each contrib-
ute to reducing 3-MCA-induced tumor formation and
growth [44]. The immune system can drive tumors into
a dormant state, which in turn affects immunoediting
and tumorigenicity, as reviewed [44].
Defects in IFN signaling can augment tumorigenesis in
the 3-MCA-sarcoma model; evidence from USP18 null
mice identified an amplified IFN response as compared to
wild-type mice, which is thought to provide a less permis-
sive environment for tumors [45]. To directly explore the
role of IFN signaling in leiomyosarcoma development it
would prove informative in the future to cross the USP18
null mice with mice lacking either IFN or the IFN recep-
tor (IFNGR1). However, transplantation of KHC-1 cells
into immunocompentent mice did not result in a promin-
ent immune cell response (data not shown), arguing
against a driving role for the immune system in suppress-
ing development of these leiomyosarcomas.
Abundant USP18 immunostaining in vascular smooth
muscle cells implied that sarcomas seen in these mice
could be of vascular origin. USP18 expression levels in
clinical leiomyosarcoma varied widely with some stain-
ing at levels comparable to vascular smooth muscle and
some with much lower levels (Fig. 5a and Additional file
1: Table S2). A significant association between USP18
levels and time to onset of metastasis was determined
confirming a link between USP18 levels and disease pro-
gression, as shown in Fig. 5.
Sarcomas were not seen in the original report of USP18
null mice likely because this was in the C57/Bl6 and 129
mixed strain background. These mice developed neuro-
logical symptoms that reduced their survival to less than
20 weeks of age [21]. In marked contrast, USP18 null mice
in this study had been bred onto the FVB/N strain back-
ground and rarely exhibited neurological symptoms.
USP18 null mice developed leiomyosarcomas with com-
plex karyotypes and distinct genetic alterations reminis-
cent of human leiomyosarcomas. Common alterations
included MYC overexpression and P53 stabilization. The
genetic variability of leiomyosarcoma makes it essential to
have different models in which to test antineoplastic drug
treatments. Loss of PTEN sensitized leiomyosarcoma cells
to rapamycin treatment [41], however tumors with differ-
ent driver mutations will likely have different drug
sensitivities.
Loss of USP18 activity is associated with type 1 IFN
hypersensitivity [21]. Both murine USP18 null and hu-
man leiomyosarcoma cell lines described here responded
independently to doxorubicin and type 1 IFN treat-
ments. Activating the IFN pathway either directly with
IFN or with an IFN-inducing agent might target leio-
myosarcomas. Murine leiomyosarcoma cell lines also ex-
hibited constitutive activation of phosphorylated STAT3
(pSTAT3). JAK2-STAT3 inhibitor treatment of these sar-
coma cells led to downregulation of pSTAT3 and growth
inhibition, indicating this type of inhibitor presents a
potential treatment for leiomyosarcomas (Additional file
1: Figure. S2).
USP18 is the major deconjugase for ISG15, a type 1 IFN-
regulated ubiquitin-like protein modifier [18]. Decrease in
USP18 has not been previously associated with sarcoma
development. Conversely, USP18 repression has been asso-
ciated with antineoplastic effects in lung and kidney cancers
and in acute promyelocytic leukemia [26–28]. Immunohis-
tochemical analysis of human tissues showed high levels of
USP18 expression in normal vascular smooth muscle cells
from which these tumors are likely derived [38]. IFN is
known to stimulate vascular smooth muscle cell prolifera-
tion via PI3K and mTOR signaling [46]. The IFN-
hypersensitive environment found in USP18 null mice
might deregulate proliferation of these vascular cells, initiat-
ing leiomyosarcoma formation. This possibility is consistent
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with the leiomyosarcoma formation seen when PI3K/
mTOR signaling is inappropriately activated in smooth
muscle cells by deletion of the negative regulator, PTEN
[41].
Conclusions
This study reports a new murine model of spontaneous
leiomyosarcoma with associated transplantable cell lines.
The tumors exhibited many features of human leiomyosar-
comas including aneuploidy, MYC amplification and P53
stabilization. Sarcomas rapidly developed after transplant-
ation of murine leiomyosarcoma cell lines into recipient
mice, making this a tractable model for testing innovative
leiomyosarcoma therapies. Taken together, these models
can provide insights into both leiomyosarcoma biology and
therapy.
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of growth in mice. Immunoblot analysis of protein isolated from 4 control and
4 USP18 overexpressing independent orthotopic sarcomas harvested from
mice. The immunoblot showed representative analysis of KHC-2 cells and this
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